Enzychem Lifesciences Corporation (183490.KQ)

2,055.00 +55.00 (+2.75%) At close: 03:30PM KST

Enzychem Lifesciences Corporation

aT Center
10th Floor 27 Gangnamdae-ro Seocho-gu
Seoul
South Korea
82 2 501 1084
https://www.enzychem.com

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Ki-Young Sohn	Chairman & Chief Executive Officer	N/A	N/A	N/A
Mr. Alexander Fleming M.D., Ph.D.	Member of Corporate Advisory Committee & CTO	N/A	N/A	N/A
Mr. Do-Young Lee	Chief Scientific Officer & Member of the Board of Directors	N/A	N/A	N/A
Myung-Hwan Kim M.D., Ph.D.	CMO & Director	N/A	N/A	N/A
Dr. Jeff Clark	Chief Licensing Officer	N/A	N/A	N/A
Mr. John Choi	Executive Director	N/A	N/A	N/A
Jae-Yong Lee	VP & Executive Director	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea.

Corporate governance

Enzychem Lifesciences Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.